- Home
- SGN vs GRI Comparison
SGN vs GRI Comparison
Compare SGN & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- GRI
- Stock Information
- Founded
- SGN 2019
- GRI 2018
- Country
- SGN United States
- GRI United States
- Employees
- SGN N/A
- GRI N/A
- Industry
- SGN
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- GRI Health Care
- Exchange
- SGN Nasdaq
- GRI Nasdaq
- Market Cap
- SGN 3.8M
- GRI 3.6M
- IPO Year
- SGN 2023
- GRI N/A
- Fundamental
- Price
- SGN $1.59
- GRI $1.66
- Analyst Decision
- SGN
- GRI Strong Buy
- Analyst Count
- SGN 0
- GRI 2
- Target Price
- SGN N/A
- GRI $22.00
- AVG Volume (30 Days)
- SGN 284.6K
- GRI 98.9K
- Earning Date
- SGN 08-12-2025
- GRI 08-14-2025
- Dividend Yield
- SGN N/A
- GRI N/A
- EPS Growth
- SGN N/A
- GRI N/A
- EPS
- SGN N/A
- GRI N/A
- Revenue
- SGN $391,126.00
- GRI N/A
- Revenue This Year
- SGN N/A
- GRI N/A
- Revenue Next Year
- SGN N/A
- GRI N/A
- P/E Ratio
- SGN N/A
- GRI N/A
- Revenue Growth
- SGN N/A
- GRI N/A
- 52 Week Low
- SGN $0.44
- GRI $1.10
- 52 Week High
- SGN $36.70
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- SGN 52.64
- GRI 61.33
- Support Level
- SGN $1.47
- GRI $1.33
- Resistance Level
- SGN $1.65
- GRI $1.45
- Average True Range (ATR)
- SGN 0.10
- GRI 0.10
- MACD
- SGN 0.00
- GRI 0.03
- Stochastic Oscillator
- SGN 71.13
- GRI 97.06
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.